MAIA Biotechnology, Inc.

MAIA

US5526411021

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:00 2026-06-05 pm EDT			5-day change	1st Jan Change
1.360 ^USD	-9.33%		-2.16%	-11.11%

Jun. 04	MAIA Biotechnology Says 29 Patients Dosed in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer Treatment	MT
Jun. 04	MAIA Biotechnology, Inc. Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial	CI

MAIA Gets FDA Clearance for Enrollment in Expanded Phase 2 Cancer Study

Published on 06/03/2026 at 10:24 am EDT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about MAIA Biotechnology, Inc.

Jun. 04	MAIA Biotechnology Says 29 Patients Dosed in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer Treatment	MT
Jun. 04	MAIA Biotechnology, Inc. Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial	CI
Jun. 03	Maia Biotechnology Receives Fda Clearance to Open U.S. Enrollment in Ongoing Phase 2 Thio-101 Trial Expansion	CI
Jun. 03	MAIA Gets FDA Clearance for Enrollment in Expanded Phase 2 Cancer Study	MT
Jun. 01	Maia Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent At 2026 Annual Meeting of American Society of Clinical Oncology	CI
May. 14	Maia Biotechnology - to terminate at the market offering agreement effective May 23, 2026 - SEC filing	RE
May. 11	MAIA Biotechnology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 30	Certain Warrants of MAIA Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2026.	CI
Apr. 30	Certain Options of MAIA Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2026.	CI
Apr. 30	38,659,579 Common Stock of MAIA Biotechnology, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2026.	CI
Apr. 16	Maia Biotechnology Inc Activates First US Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non Small Cell Lung Cancer	CI
Mar. 31	MAIA Biotechnology, Inc. Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer	CI
Mar. 31	Maia biotechnology reports overall survival exceeding two years for eight patients in ongoing phase 2 clinical trial in non-small cell lung cancer	RE
Mar. 23	MAIA Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 04	Maia Biotechnology Inc enters underwriting agreement with Konik Capital Partners - SEC filing	RE

Chart MAIA Biotechnology, Inc.

Duration

Period

MAIA: Dynamic Chart

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company's THIO (6-thio-dG, 6-thio-2'-deoxyguanosine), is a lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The modified nucleotide 6-thio-2-deoxyguanosine (THIO) induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment with THIO followed by PD-(L)1 inhibitors resulted in tumor regression in advanced, in vivo cancer models by induction of cancer type-specific immune memory. THIO is being developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

Employees

Sector

Biotechnology & Medical Research

More about the company